Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × aflutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 27 NSCLC 8 Meningeal Carcinomatosis 4 Brain Neoplasms 4 Adenocarcinoma of Lung 4 Lung Neoplasms 3 Respiratory Tract Neoplasms 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasm, Residual 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Bronchial Neoplasms 1 Advanced Non-small Cell Lung Cancer 1 Advanced NSCLC Patients With T790M 1 Advanced NSCLC 1 Advanced Lung Cancer 1 Adenocarcinoma 1

Interventions

Cisplatin 43 Carboplatin 39 pembrolizumab 37 Paclitaxel 33 Gemcitabine 27 Radiotherapy 18 Pemetrexed 18 Magnetic Resonance Spectroscopy 17 Radiotherapy, Intensity-Modulated 16 Docetaxel 16 Cetuximab 16 Specimen Handling 14 Nivolumab 14 Cyclophosphamide 13 durvalumab 12 Fluorouracil 12 Sorafenib 10 130-nm albumin-bound paclitaxel 10 Sunitinib 9 Platinum 9 Bevacizumab 9 osimertinib 8 Radiation 8 1,2-diaminocyclohexaneplatinum II citrate 8 Oxaliplatin 7 Irinotecan 7 Everolimus 7 Drug Therapy 7 Capecitabine 7 fludarabine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Recruiting

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡